Patients who had type 2 diabetes and cardiovascular risk factors who took dapagliflozin had a 19% lower risk of a first atrial fibrillation or atrial flutter event, compared with patients taking a placebo, a study in Circulation showed. Total AFib and atrial flutter events also was lower among patients taking dapagliflozin, compared with those taking a placebo.
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.